Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$43.30
-3.20-6.88%
Pre-Market: 6:29 AM EDT
Comments
Loading...
Protagonist Therapeutics Analyst Ratings and Price Targets | NASDAQ:PTGX | Benzinga
Protagonist Therapeutics Inc has a consensus price target of $57.75 based on the ratings of 13 analysts. The high is $80 issued by HC Wainwright & Co. on March 11, 2025. The low is $30 issued by SVB Leerink on May 5, 2022. The 3 most-recent analyst ratings were released by Wedbush, Truist Securities, and BMO Capital on March 28, 2025, March 11, 2025, and March 11, 2025, respectively. With an average price target of $72.67 between Wedbush, Truist Securities, and BMO Capital, there's an implied 67.82% upside for Protagonist Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Wedbush
Truist Securities
BMO Capital
HC Wainwright & Co.
Citizens Capital Markets
1calculated from analyst ratings
Analyst Ratings for Protagonist Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 03/28/2025 | Buy Now | 61.66% | Wedbush | Yun Zhong35% | $70 → $70 | Reiterates | Outperform → Outperform | Get Alert |
| 03/11/2025 | Buy Now | 75.52% | Truist Securities | Srikripa Devarakonda45% | $60 → $76 | Maintains | Buy | Get Alert |
| 03/11/2025 | Buy Now | 66.28% | BMO Capital | Etzer Darout44% | $62 → $72 | Reiterates | Outperform → Outperform | Get Alert |
| 03/11/2025 | Buy Now | 84.76% | HC Wainwright & Co. | Douglas Tsao51% | $54 → $80 | Maintains | Buy | Get Alert |
| 03/10/2025 | Buy Now | 40.88% | Citizens Capital Markets | Jonathan Wolleben63% | $61 → $61 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 03/10/2025 | Buy Now | 24.71% | HC Wainwright & Co. | Douglas Tsao51% | $54 → $54 | Reiterates | Buy → Buy | Get Alert |
| 03/04/2025 | Buy Now | 31.64% | JP Morgan | Brian Cheng37% | $53 → $57 | Maintains | Overweight | Get Alert |
| 03/03/2025 | Buy Now | 24.71% | HC Wainwright & Co. | Douglas Tsao51% | $54 → $54 | Reiterates | Buy → Buy | Get Alert |
| 02/24/2025 | Buy Now | -12.24% | Goldman Sachs | — | $43 → $38 | Maintains | Neutral | Get Alert |
| 02/24/2025 | Buy Now | 24.71% | HC Wainwright & Co. | Douglas Tsao51% | $50 → $54 | Maintains | Buy | Get Alert |
| 02/07/2025 | Buy Now | 33.95% | JMP Securities | Jonathan Wolleben63% | $58 → $58 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 02/07/2025 | Buy Now | 15.47% | HC Wainwright & Co. | Douglas Tsao51% | $50 → $50 | Reiterates | Buy → Buy | Get Alert |
| 02/04/2025 | Buy Now | 22.4% | JP Morgan | Brian Cheng37% | $51 → $53 | Maintains | Overweight | Get Alert |
| 12/10/2024 | Buy Now | 15.47% | HC Wainwright & Co. | Douglas Tsao51% | $50 → $50 | Reiterates | Buy → Buy | Get Alert |
| 12/06/2024 | Buy Now | 43.19% | BMO Capital | Etzer Darout44% | → $62 | Initiates | → Outperform | Get Alert |
| 11/22/2024 | Buy Now | 15.47% | HC Wainwright & Co. | Douglas Tsao51% | $50 → $50 | Reiterates | Buy → Buy | Get Alert |
| 11/19/2024 | Buy Now | 15.47% | HC Wainwright & Co. | Douglas Tsao51% | $50 → $50 | Reiterates | Buy → Buy | Get Alert |
| 11/11/2024 | Buy Now | 15.47% | HC Wainwright & Co. | Douglas Tsao51% | $50 → $50 | Reiterates | Buy → Buy | Get Alert |
| 11/05/2024 | Buy Now | 33.95% | Wedbush | Yun Zhong35% | → $58 | Initiates | → Outperform | Get Alert |
| 09/24/2024 | Buy Now | 50.12% | TD Cowen | Tara Bancroft64% | → $65 | Initiates | → Buy | Get Alert |
| 09/12/2024 | Buy Now | 15.47% | HC Wainwright & Co. | Douglas Tsao51% | $40 → $50 | Maintains | Buy | Get Alert |
| 09/09/2024 | Buy Now | 38.57% | Truist Securities | Srikripa Devarakonda45% | → $60 | Initiates | → Buy | Get Alert |
| 08/07/2024 | Buy Now | -0.69% | JMP Securities | Jonathan Wolleben63% | $45 → $43 | Maintains | Market Outperform | Get Alert |
| 08/07/2024 | Buy Now | -7.62% | HC Wainwright & Co. | Douglas Tsao51% | $38 → $40 | Maintains | Buy | Get Alert |
| 07/25/2024 | Buy Now | 10.85% | JP Morgan | Brian Cheng37% | $39 → $48 | Maintains | Overweight | Get Alert |
| 07/24/2024 | Buy Now | 17.78% | BTIG | Julian Harrison40% | $41 → $51 | Maintains | Buy | Get Alert |
| 06/17/2024 | Buy Now | 3.93% | JMP Securities | Jonathan Wolleben63% | $45 → $45 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 06/14/2024 | Buy Now | -12.24% | HC Wainwright & Co. | Douglas Tsao51% | $38 → $38 | Reiterates | Buy → Buy | Get Alert |
| 05/09/2024 | Buy Now | -12.24% | HC Wainwright & Co. | Douglas Tsao51% | $38 → $38 | Reiterates | Buy → Buy | Get Alert |
| 05/08/2024 | Buy Now | 3.93% | JMP Securities | Jonathan Wolleben63% | $42 → $45 | Maintains | Market Outperform | Get Alert |
| 03/11/2024 | Buy Now | -3% | JMP Securities | Jonathan Wolleben63% | $42 → $42 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 03/11/2024 | Buy Now | -12.24% | HC Wainwright & Co. | Douglas Tsao51% | $38 → $38 | Maintains | Buy | Get Alert |
| 02/28/2024 | Buy Now | -12.24% | HC Wainwright & Co. | Douglas Tsao51% | $38 → $38 | Reiterates | Buy → Buy | Get Alert |
| 02/28/2024 | Buy Now | -14.55% | JP Morgan | Brian Cheng37% | $34 → $37 | Maintains | Overweight | Get Alert |
| 11/03/2023 | Buy Now | -14.55% | JMP Securities | Jonathan Wolleben63% | $35 → $37 | Maintains | Market Outperform | Get Alert |
| 10/30/2023 | Buy Now | — | Capital One | Tim Chiang38% | — | Initiates | → Overweight | Get Alert |
| 10/10/2023 | Buy Now | -12.24% | HC Wainwright & Co. | Douglas Tsao51% | → $38 | Reiterates | Buy → Buy | Get Alert |
| 09/25/2023 | Buy Now | -21.48% | JP Morgan | Brian Cheng37% | $36 → $34 | Maintains | Overweight | Get Alert |
| 08/04/2023 | Buy Now | -12.24% | HC Wainwright & Co. | Douglas Tsao51% | → $38 | Reiterates | Buy → Buy | Get Alert |
| 07/10/2023 | Buy Now | -12.24% | HC Wainwright & Co. | Douglas Tsao51% | → $38 | Reiterates | Buy → Buy | Get Alert |
| 07/06/2023 | Buy Now | -19.17% | JMP Securities | Jonathan Wolleben63% | $28 → $35 | Maintains | Market Outperform | Get Alert |
| 07/03/2023 | Buy Now | -19.17% | Piper Sandler | Yasmeen Rahimi60% | → $35 | Reiterates | Overweight → Overweight | Get Alert |
| 07/03/2023 | Buy Now | -5.31% | BTIG | Julian Harrison40% | → $41 | Reiterates | → Buy | Get Alert |
| 06/12/2023 | Buy Now | -12.24% | HC Wainwright & Co. | Douglas Tsao51% | → $38 | Reiterates | Buy → Buy | Get Alert |
| 04/27/2023 | Buy Now | -12.24% | HC Wainwright & Co. | Douglas Tsao51% | → $38 | Reiterates | → Buy | Get Alert |
| 03/16/2023 | Buy Now | -35.33% | JMP Securities | Jonathan Wolleben63% | $31 → $28 | Maintains | Market Outperform | Get Alert |
| 03/16/2023 | Buy Now | -12.24% | HC Wainwright & Co. | Douglas Tsao51% | $33 → $38 | Maintains | Buy | Get Alert |
| 03/08/2023 | Buy Now | -28.41% | JMP Securities | Jonathan Wolleben63% | $21 → $31 | Maintains | Market Outperform | Get Alert |
| 11/10/2022 | Buy Now | -23.79% | HC Wainwright & Co. | Douglas Tsao51% | $50 → $33 | Maintains | Buy | Get Alert |
| 08/25/2022 | Buy Now | -51.5% | JMP Securities | Jonathan Wolleben63% | → $21 | Reinstates | → Market Outperform | Get Alert |
| 05/18/2022 | Buy Now | -19.17% | Piper Sandler | Yasmeen Rahimi60% | $60 → $35 | Maintains | Overweight | Get Alert |
| 05/05/2022 | Buy Now | -30.72% | SVB Leerink | Joseph Schwartz65% | $50 → $30 | Maintains | Outperform | Get Alert |
FAQ
What is the target price for Protagonist Therapeutics (PTGX) stock?
The latest price target for Protagonist Therapeutics (NASDAQ:PTGX) was reported by Wedbush on March 28, 2025. The analyst firm set a price target for $70.00 expecting PTGX to rise to within 12 months (a possible 61.66% upside). 30 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Protagonist Therapeutics (PTGX)?
The latest analyst rating for Protagonist Therapeutics (NASDAQ:PTGX) was provided by Wedbush, and Protagonist Therapeutics reiterated their outperform rating.
When was the last upgrade for Protagonist Therapeutics (PTGX)?
There is no last upgrade for Protagonist Therapeutics
When was the last downgrade for Protagonist Therapeutics (PTGX)?
There is no last downgrade for Protagonist Therapeutics.
When is the next analyst rating going to be posted or updated for Protagonist Therapeutics (PTGX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Protagonist Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Protagonist Therapeutics was filed on March 28, 2025 so you should expect the next rating to be made available sometime around March 28, 2026.
Is the Analyst Rating Protagonist Therapeutics (PTGX) correct?
While ratings are subjective and will change, the latest Protagonist Therapeutics (PTGX) rating was a reiterated with a price target of $70.00 to $70.00. The current price Protagonist Therapeutics (PTGX) is trading at is $43.30, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.